DCs, particularly the conventional type I dendritic cells (cDC1), contribute to anti‐tumor immunity by their ability to present tumor antigens and to secrete cytokines that regulate T cell survival and effector function.[19, 20] The intra‐tumoral cDC1 attracts T cells into tumors,[21] re‐stimulates and expands the tumor‐specific CD8+ T cells,[22] and supports T cell effector function by promoting T cell stemness.[18] DCs are regulated by factors in the tumor microenvironment (TME;[23]). This evidence concerns the gene CD8A and neoplasm.